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Gene expression analysis of a murine model with
pulmonary vascular remodeling compared to
end-stage IPAH lungs
Kayoko Shimodaira1,2, Yoichiro Okubo1, Eri Ochiai3,4, Haruo Nakayama1, Harutaka Katano5, Megumi Wakayama1*,
Minoru Shinozaki1, Takao Ishiwatari1, Daisuke Sasai1, Naobumi Tochigi1, Tetsuo Nemoto1, Tsutomu Saji2,
Katsuhiko Kamei3 and Kazutoshi Shibuya1,6

Abstract
Background: Idiopathic pulmonary arterial hypertension (IPAH) continues to be one of the most serious intractable
diseases that might start with activation of several triggers representing the genetic susceptibility of a patient. To
elucidate what essentially contributes to the onset and progression of IPAH, we investigated factors playing an
important role in IPAH by searching discrepant or controversial expression patterns between our murine model and
those previously published for human IPAH. We employed the mouse model, which induced muscularization of
pulmonary artery leading to hypertension by repeated intratracheal injection of Stachybotrys chartarum, a member
of nonpathogenic and ubiquitous fungus in our envelopment.
Methods: Microarray assays with ontology and pathway analyses were performed with the lungs of mice. A
comparison was made of the expression patterns of biological pathways between our model and those published
for IPAH.
Results: Some pathways in our model showed the same expression patterns in IPAH, which included bone
morphogenetic protein (BMP) signaling with down-regulation of BMP receptor type 2, activin-like kinase type 1, and
endoglin. On the other hand, both Wnt/planar cell polarity (PCP) signaling and its downstream Rho/ROCK signaling
were found alone to be activated in IPAH and not in our model.
Conclusions: Activation of Wnt/PCP signaling, in upstream positions of the pathway, found alone in lungs from
end stage IPAH may play essential roles in the pathogenesis of the disease.
Keywords: Pulmonary Vascular Remodeling, Stachybotrys chartarum, BMP signaling, BMPR2, PCP pathway

Background
Pulmonary hypertension is a hemodynamic state characterized by elevation of the mean pulmonary arterial pressure leading to right ventricular (RV) failure and
premature death. Pulmonary arterial hypertension
(PAH) affects the small muscular arteries and arterioles
in the lung and is histologically characterized by endothelial and smooth muscle cell proliferation, medial
thickening, and thrombosis in situ. Idiopathic pulmonary
arterial hypertension (IPAH), one of 6 subcategories
* Correspondence: megumi.wakayama@med.toho-u.ac.jp
1
Department of Surgical Pathology, Toho University School of Medicine,
6-11-1 Omori-Nishi, Ota-Ku, Tokyo 143-8541, Japan
Full list of author information is available at the end of the article

proposed by Dana Point Classification [1], accounts for
approximately half of PAH cases [2] and up to 40% of
patients with no family history carries mutations in the
bone morphogenetic protein receptor type 2 (BMPR2)
gene [1]. 7% of patients with IPAH has a family history
[3], and about 70% of these have long been recognized
and are usually due to mutations in BMPR2, or much
less commonly, 2 other members of the transforming
growth factor superfamily, activin-like kinase type 1
(ALK1) and endoglin (ENG) [1]. While BMPR2 mutation strongly predisposes to IPAH, only 20% of mutation
carriers develop a clinical disease [4]. This finding suggests that the development of IPAH first requires a genetic susceptibility, followed by one or several secondary
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triggering factors such as modifier genes and some sort
of stimulus [5]. However, the pathogenesis of IPAH
remains unclear.
To elucidate the pathophysiology of IPAH, we conducted genome-wide analysis of RNA expression profiles
in lungs obtained from the murine model, which showed
a favorable reproducibility to remodel pulmonary arteries induced by inoculation of Stachybotrys chartarum,
an ubiquitous fungus in the surrounding environment
[6]. This was followed in the study by exploration for
factors playing a significant role in the onset of IPAH by
searching discrepant or controversial expression patterns
between in the model and those in IPAH previously
published.

Methods
Detection of S. genes in the human lung tissue of IPAH
patients and controls by nested polymerase chain
reaction (PCR)

Upon getting the informed consent from patient’s family,
a part of lung tissue obtained at autopsy from 9 children
(under 18 years of age) with IPAH and 9 age-matched
controls for detection of S. DNA in the tissue of human
lung. It had been confirmed that none of them had inflammatory changes or other kind of infection in lungs
by histopathological examination before DNA preparation. This protocol was approved by ethical committee
of Toho University School of Medicine (# 20029). Using
DNA isolated from the lung tissue, nested PCR and gel
electrophoresis were performed in the usual manner.
The following primers were used for identification of S.
gene from autopsied lungs [7,8]: a primary primer of a
two-step nested assay, forward primer S-Chart-tri5-F25 0-TACACCAG G GAG GAGCG TG T T-30 and reverse
primer S-Chart-tri5-R2-50- GCCGACAAT GGT TCGAA
GGGA-30 produced a product of 138 bp. For the nested
PCR primers, forward primer S-Chart-tri5-F2n-5 0-GAAA
ATCTCCAGTATGCCT-30 and reverse primer S-Charttri5-R2n-50-AGCCTCCAGTCTCTTGGGG-30 produced a
product of 96 bp. For β-actin, the control for DNA quality,
a two-step nested assay was also used with the following
primers: forward primer B3-50-ACACAACTGTGTT
CACTAGC-30 and reverse primer B4-50-CAACTTCATC
CACGTTCACC-30 produced a product of 110 bp. For the
nested PCR primers, forward primer b-globin-nestF34-5250-AACCTCAAACAGACACCAT-30 and reverse primer
b-globin-nestR103-85-50-TTGCCCCACAGGGCAGTAA30 produced a product of 70 bp. The PCR amplification
was performed as follows: initial denaturation at 94°C for
2 min, followed by 35 cycles of denaturation at 94°C for
30 s, annealing at 55°C for 30 s, with an extension at
72°C for 30 s, and a final extension at 72°C for 7 min.
The second-round PCR reactions were performed in a
manner identical to that applied for the first strand PCR,
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except for using different sets of primers. The PCR products were analyzed by electrophoresis on an agarose gel
stained with ethidium bromide upon preparation.
Fungal preparation and intratracheal injection

S. chartarum (IFM 53637), which produces trichothecene mycotoxins, was isolated from house dust in Japan,
and has been stored in the culture collection of the
Medical Mycology Research Center, Chiba University.
The fungus was grown on potato dextrose agar (PDA)
slants for 3 weeks at 25°C. Spores were collected in
RPMI1640 medium (Sigma, St. Louis, MO, USA) and
the concentration was adjusted to 4 × 105 spores / ml.
Spore concentrations and appearance of the suspension
were evaluated under light microscopy before use. Sixweek-old male ddY mice (Tokyo Laboratory Animals
Science, Tokyo, Japan) were employed in this study.
Mice were lightly anaesthetized with an intraperitoneal
injection of ketamine (65 mg/kg BW) and xylazine
(13 mg/kg BW). Their mean weight was 27.4 ± 1.21 g.
The mice were placed in a supine position and a 24 G
intravascular catheter (Insyte-W; Becton-Dickinson,
Sandy, UT, USA) was then inserted intratracheally. The
spore suspension (25 μl / mouse) containing 1 × 104
spores was injected through the catheter into the trachea
of each mouse 12 times at 4–5 day intervals for 8 weeks
(n = 3) as described previously [6]. Control mice (n = 3)
were injected with the same volume of RPMI-1640
medium rather than the spore suspension. All mice were
cared for in accordance with the rules and regulations
set out by the Prime Minister’s Office of Japan. Animal
protocols were approved by the Special Committee on
Animal Welfare of Chiba University. (DOU: 21–65).
Histopathology and morphometric analysis of pulmonary
arteries

Mice were sacrificed using by an overdose of diethyl
ether inhalation 7 days after the last injection. Lungs
were removed and fixed with a 10% formaldehyde solution, embedded in paraffin, cut into 3 μm-thick sections,
and stained with hematoxylin and eosin for histopathological examination. Elastic fiber was stained with
Elastica-van Gieson staining (Muto pure chemicals,
Tokyo, Japan). Morphometric analyses were performed
to determine the luminal stenosis of the pulmonary arteries. At least 200 pulmonary arteries per lung section
from each mouse were chosen at random and examined.
Cross-sections of arteries observed in the section were
used to measure the distance between the external elastic lamina, internal elastic lamina, and intravascular
lumen. All images were analyzed using IMAGE J 1.36b
software (National Institutes of Health, Bethesda, MD,
USA). The stricture rate was therefore calculated.
Morphometry measurements were performed according
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to the techniques described in Dail and Hammar’s Pulmonary Pathology [9]. The thickness of media was calculated by subtracting the distance between the internal
elastic lamina from that of the external lamina, and the
thickness of the intima was calculated by subtracting the
distance between the intravascular lumen from that of
the internal elastic lamina. The distance between the external elastic lamina of the artery was defined as the
diameter. Arteries were divided into three groups
according to diameter: 50 < μm, 50–100 μm, and
>100 μm. Data are given as mean ± SD. Statistical analyses were performed using Mann-Whitney's U test. Differences were considered significant at P < 0.05.
RNA isolation and quality identification

RNA was isolated from the whole lung homogenates for
both microarray analysis and Real-time (RT) Quantitative PCR with the RNeasy Lipid Tissue Mini Kit (Qiagen,
Alameda, CA, USA) according to the manufacturer’s
instructions and stored at −80°C. Total RNA quality was
assessed and confirmed using the Agilent Bioanalyzer
2100 (Agilent Technologies, Palo Alto, CA, USA) for
visualization of the 28S and 18S rRNA bands. RNA concentration and purity were also assessed and confirmed
using the UV spectrophotometer NanoDrop™ND-1000
(NanoDrop Technologies, Wilmington, DE, USA), which
calculates 260/280 ratios.
RNA preparation for microarray analysis

cDNA preparation and microarray analysis were conducted at Bio Matrix Research (Chiba, Japan) using the
Affymetrix system (Santa Clara, CA, USA). Isolated total
RNA (100 μg) was converted into double-stranded
cDNA using 30IVT Express kit (Affymetrix, Santa Clara,
CA, USA), which was purified using a GeneChip Sample
Cleanup Module (Affymetrix, Santa Clara, CA, USA). In
vitro transcription reactions were performed using a
GeneChip IVT Labeling Kit, which includes T7 RNA
polymerase and biotin-labeled ribonucleotides. Biotinlabeled cRNA was purified using a GeneChip Sample
Cleanup Module. The concentration of cRNA was calculated from light absorbance at 260 nm using a UV spectrophotometer. cRNA (15 mg) was then fragmented at
94°C in the presence of a fragmentation buffer (Affymetrix, Santa Clara, CA, USA). The labeled cRNA was
purified, fragmented, and spiked with in vitro transcription controls.
Microarray analysis

Mouse Genome 430 2.0 microarrays (Affymetrix, Santa
Clara, CA, USA) were hybridized with 12.5 μg of cRNA.
The array was incubated for 16 hr at 45°C, and automatically washed and stained with the GeneChip
Hybridization, Wash and Stain Kit (Affymetrix, Santa
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Clara, CA, USA) on an Affymetrix GeneChip Fluidics
station. The arrays were analyzed using the GeneChip
Scanner 3000. All preparations were run on qualitycontrolled chips and had 30/50 signal ratios of less than 3.
The expression value of the transcript was computed
using Affymetrix® GeneChip® Command Console®
Software (AGCC) with the MAS5 algorithm [10], in
which the probabilities of the values of each transcript
were indicated as the “Flag” Present (p ≼0 to <0.04),
Marginal (p ≼0.04 to <0.06), and Absent (p ≼ 0.06 to
<0.5). Further analysis was performed with probes that
had a present call in all analyzed samples. For analysis,
the data were normalized using GeneSpring® GX 10.0
(Agilent Technologies, Palo Alto, CA, USA) data-mining
software, per-chip normalization to the 50th percentile
of the measurements for the array, and per-gene by normalizing to the median measurement for the gene across
all the arrays in the data set. In addition, fold changes
were calculated by this software for each gene between
the experimental groups and controls. Statistically significant differences were investigated by means of unpaired t-tests. Gene expression differences with p < 0.05
and at least a ±1.3-fold change were considered statistically significant. We employed the Biological Networks
Gene Ontology (GO) tool BINGO [11] (http://www.psb.
ugent.be/cbd/papers/BiNGO) to find statistically overor under-represented GO categories in biologic data as
the tool for GO analysis of the stored genes. The analysis
was done using the ‘hyper geometric test’, and all GO
biological process terms that were significant with
P < 0.05 (after correcting for multiple term testing using
Benjamin and Hochberg false discovery rate corrections)
were selected as over-represented and under-represented.
Furthermore, the open access and curated pathway
database REACTOME [12] (http://www.reactome.org)
was used to determine which events (reactions and/or
pathways) were statistically overrepresented in a set
of genes.
RT Quantitative PCR for evaluating the microarray results

cDNA preparation and RT-PCR were performed at Bio
Matrix Research (Chiba, Japan). 2 μg of isolated RNA
was used for cDNA synthesis (40 μl) using a Superscript
III First Strand Synthesis System (Invitrogen, Carlsbad,
CA, USA). To evaluate the concentration and purity of
cDNA, 260/280 ratios were calculated using the UV
spectrophotometer NanoDrop™ND-1000 (NanoDrop
Technologies, Wilmington, DE, USA). PCR was performed in a 15 μl reaction mixture containing 1 μl of
sample cDNA, 0.75 μl of TaqMan® Gene Expression
Assays, 7.50 μl of TaqMan Universal PCR Master Mix,
and 5.75 μl of RNase / DNase free water (Applied Biosystems, Foster City, CA, USA). 15 μl of PCR reaction
mix was transferred into a 384-well reaction plate. The
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primer sequences are given in Table 1. Gene expression
was measured on a 7900HT Fast RT-PCR system (Applied Biosystems, Foster City, CA, USA) with cycle conditions of 50°C/2 min, 95°C/10 min, 95°C/15 sec, and
60°C/1 min (steps 3–4 were repeated 40 times). Assay
results were collected and analyzed using SDS 2.2 software (Applied Biosystems, Foster City, CA, USA). Each
value is the mean of three biological replicates. Data are
given as mean ± SD. Statistical analyses were performed
by non-paired t-tests. Differences were considered significant at P < 0.05.
Literature search concerning gene expression pattern in
IPAH

We used PubMed (http://www.ncbi.nlm.nih.gov/pubmed/)
to search for previous studies published since 2000 that
analyzed biological molecules with altered expression using
lung samples isolated from IPAH, compared with normal
control or secondary PAH. From microarray studies, we referred to open access data stored in Gene Expression
Omnibus: GEO (http://www.ncbi.nlm.nih.gov/geo/) and
identified the genes that were differentially expressed following the methods described in each study. GO and
Pathway analysis were performed on the genes in the
same way as we done on our data.
Comparing expression patterns of molecules between
IPAH and experimental model

The biological molecules reported in various studies
were collected and divided into groups according to the
gene ontology biological process and pathways using the
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Gene Ontology Annotation Database GOA [13] (http://
www.ebi.ac.uk/GOA/), REACTOME [12], and KEGG
[14] (http://www.genome.jp/kegg/). The expression pattern of each group in IPAH was compared with our
PAH models.

Results
Detection of S. genes in human lung tissue from patients
with IPAH and controls by nested PCR

S. chartarum DNA was detected in 6 of 9 lung samples
among both two groups, children with IPAH and agematched controls (Figure 1). There was no difference in
the frequency (approximately 70%) of the detection in
children, with or without of IPAH.
Pathological findings in experimental PAH

Diffuse symmetric thickening of intima and media in the
pulmonary artery was shown in the experimental group
(Figure 2). The thickened intima and media were accompanied by proliferation of myointimal and smooth
muscle cells, respectively. None of arteries showed
alterations corresponding to necrosis, thrombosis, and
plexiform lesions. The changes developed in arteries of
small and medium-sized were mostly uniform. The
thickened intima and media were statistically significant
regardless of the size of vessels (Figure 3).
In this model, no venous canals were altered. None
were found of components from injected fungus (spores
and hyphae) and changes likely induced by the injection,
such as perivascular cuffing and intraalveolar inflammatory exudates.

Table 1 Primers used in RT-PCR
RefSeq†

Gene Symbol

Assay ID*

Acvrl1

Mm03053695_s1

NM_009612.2

TTTGTGGGAGCACTTGGCCTGTGAC

Bmpr2

Mm01254942_m1

NM_007561.3

AGTATACAGATAGGTGAGTCAACAC

Ccl8

Mm01297184_g1

NM_021443.2

CCATGGAAGCTGTGGTTTTCCAGAC

Ccl9

Mm00441260_m1

NM_011338.2

AGATCACACATGCAACAGAGACAAA

Ear11

Mm00519056_s1

NM_053113.2

CACAACTCCGGCCAGTCATTATTCC

Eng

Mm00468256_m1

NM_001146348.1

AAAAAACACGTGCAGACTCTCCAGT

‡

Context Sequence

Gapdh

Mm99999915_g1

NM_008084.2

TGAACGGATTTGGCCGTATTGGGCG

Igj

Mm00461780_m1

NM_152839.2

TCCGAATTGTTGTCCCTTTGAACAA

Mmp12

Mm00500554_m1

NM_008605.3

AAGTTTTCAAGGCACAAACCTCTTC

Mmp13

Mm00439495_g1

NM_008607.1

GAACCACGTGTGGAGTTATGATGAT

Mmp19

Mm00491300_m1

NM_021412.1

TGGTGCTGGGGCCTCGTGGGAAGAC

Nos3

Mm01134921_g1

NM_008713.4

CGGCGTGCTGCGGGATCAGCAACGC

Pdgfa

Mm01205760_m1

NM_008808.3

GGAGGAGGAGACAGATGTGAGGTGA

Vegfa

Mm01281449_m1

NM_001025250.3

ACGTACTTGCAGATGTGACAAGCCA

*Taqman® Gene Expression Assays.
†
NCBI Gene Reference: NCBI transcript ID detected by the assay.
‡
GAPDH: Glyceraldehyde-3-phosphate dehydrogenase was used as an internal control.
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Figure 1 Detection of Stachybotrys chartarum gene in the human lung tissue of IPAH patients and controls. Agarose gel electrophoresis
showed the amplification products after nested polymerase chain reaction for S. chartarum DNA using the standard assay. P1- P2: Positive control
(96 bp and 70 bp); S1-S9: Children with IPAH; C1-C9: Age-matched control; N: Negative control (No DNA). S. chartarum and β-globin bands are 96
and 70 bp, respectively. 96 bp–specific band was detectable in P1-2, S1-2, S4, S6, S8-9, C1, C3-4, C6, C8-9.

Gene expression in the PAH model mouse

Upon normalizing the expression values for the samples,
the scatter plot of log intensity values was obtained as
shown in Figure 4. 337 and 503 genes were found to exhibit up- and down-regulation from the lungs of mice
with inoculation of the fungus in comparison to those
from the control group. The most markedly up- and
down- regulated genes are shown in Table 2. Down
regulation of BMPR2, ALK1, and ENG was found in our
PAH model. Down regulation of SMAD family member
6 expression was also observed, while the expressions of
other genes involved in bone morphogenetic protein
(BMP) signaling were unchanged. All the microarray
data are MIAME compliant and the complete microarray data were deposited in GEO (accession number
GSE23178). 696 biological process terms were detected
by GO analysis in up-regulated genes. GO terms related
to the immune system and cytokines accounted for
about 80% of total terms. Among the remaining terms,
estrogen receptor signaling pathway and serotonin transport/secretion were included. A statistically significant
biological process was not found for down-regulated
genes. Pathway analysis revealed that reactions and pathways related to the immune system, Janus kinase/signal
transducers and activators of the transcription (JAK/
STAT) pathway, and hemostasis etc. were detected
(Table 3) in up-regulated genes. Additionally, vascular
endothelial growth factor (VEGF), platelet-derived
growth factor (PDGF), apoptosis, BMP signaling, etc.
were detected in down-regulated genes.
Validation of microarray results by RT quantitative PCR
analysis

RT-PCR was used to validate 14 selected genes that were
induced or suppressed by the exposure. The correlation
of fold changes in gene expression between the arrays

and PCR is shown in Table 4. The results demonstrate
completely the same gene expression pattern between
both methods. The alterations of gene expressions were
statistically significant in BMPR2, ENG, Vascular endothelial growth factor A, Platelet-derived growth factor
alpha polypeptide, matrix metallopeptidase (MMP) 19,
MMP12, eosinophil-associated ribonuclease A family
member 11, and chemokine ligand 9.
Altered expression of biological molecules and genes in
lungs from IPAH

The biological molecules reported in previous studies
[15-28] were listed in Additional file 1. Microarray data
of patients with IPAH and normal controls were referable from 3 individual studies [15,16,27]. The numbers
of IPAH investigated in each study were 2 [16], 7 [27],
and 18 [15], the mean age and its standard deviation
were 44 ± 10 [16], 29 ± 16 [27], and 44 ± 18 [15], respectively. We analyzed the microarray data in each study
and tried to extract the genes that showed common expression patterns through these three studies. However,
there were few genes, and none of significant GO or
pathways was identified among the previous reports
regarding to IPAH.
Comparing expression patterns of molecules between
IPAH and experimental model

Events (reactions and/or pathways) and the expression
patterns in IPAH extracted from the previous reports
are listed with comparison to those resulted from our
experimental model [15-28] (Table 5).

Discussion
Since PAH is a progressive disease of unknown cause involving pulmonary arterial remodeling, characterized by
relentless deterioration and death, intense investigations
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Figure 2 Pulmonary vascular remodeling in Stachybotrys chartarum-exposed mice. Peripheral pulmonary arteries in experimental group
(A, C, and E) and control group (B, D, and F). A and B: hematoxylin and eosin double stain, C, D, E, and F: Elastic Van Gieson stain. (A) Pulmonary
vascular thickening was present over the whole lung. (C) The arterial wall shows symmetrical thickening of the intima and media. (E) This vascular
remodeling almost totally obliterates the lumens. (B, D, and F) Structure of the lung from control group is unaltered. Scale bars: 500 μm (A, B),
250 μm (C, D), and 50 μm (E, F).

have been conducted in a variety of animal models [29]
to know pathophysiology. The most commonly used
were rats exposed to either hypoxia or monocrotaline,
and newer models were introduced that involved modification of these approaches using rodents including
transgenic mice [29,30].There were at least three genomewide studies conducting rat models among them, but
little have been discussed with comparison to those in
the human disease with pathway and GO analyses [31-33].
We have therefore aimed to elucidate a part of pathophysiology of PAH accompanied by pulmonary arterial remodeling with comparison in gene expression pattern
between those previously known in end-stage IPAH and
our murine model, of which muscularization in media and

intima of pulmonary arteries was induced by inoculation
of nonpathogenic fungus [6,34]. It was found that a large
frequency of S. chartarum gene in the lung of both
children with IPAH and age-matched controls in autopsy
cases, whereas the prior histological examination had
revealed no inflammatory changes with an association to
fungal infection. The result suggests that the airway of
human generally exposed by the ubiquitous fungus.
Accordingly, unknown intrinsic factors may play a
significant role in the onset of IPAH.
It was explored in the study to search the pathways
which show common expression pattern among IPAH
patients using microarray data previously published as
well as up-loaded at the open access sites [15,16,27], but
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Figure 4 Scatter plot of microarray dataset. Gene expression
signal of control group (Y-axis) plotted against experimental
group (X-axis). The expression data are the average of three
independent gene chips for each group.

Figure 3 Morphometric analysis evaluating luminal stenosis of
pulmonary arteries. Significant thickening of both intima and
media were observed in the exposure group when compared with
the control regardless of the size of vessels. Data are presented as
means with standard error of the means. Statistical analyses were
performed using Mann-Whitney's U test. A bar with ** is significantly
different (P < 0.01).

none were elucidated. A part of the result may reflect
clinical differences in subjects such as age, gender, stage
of the disease, and etc. On the other hand, the present
murine model showed similar expression pattern of
genes which has been generally accepted as some biological molecules associated with the pathogenesis of
IPAH, such as BMP signaling [1,35,36]: BMPR2, ALK1,
and ENG. Although some of previous genome-wide analyses [31-33] conducting rat models reported alterations
of signaling pathway (Table 6), the present model
revealed more favorable similarity in number of pathways expressing same manner to IPAH. However, the result from our study might be affected by recruited
cellular components and/or reformed extracellular
matrix, because RNA was extracted from the whole lung
of the mice. Although RNA extraction was done one
week after the latest inoculation of the fungus when no
inflammatory change had been previously confirmed [6],
in vitro work evaluating cells from the lungs of the mice

would be required to look at functional alterations. In
addition, whereas multiple time point’s evaluation could
highlight the difference in pathophysiology of models of
between our mice and rats previously published, we have
evaluated once at the point when the most significant
muscularization had been confirmed [6], since a priority
in the study would have been set in comparing gene expression patterns between end-stage IPAH and our
model. It has been generally accepted that the altered
expression of BMP signaling was one of the important
molecular reactions when pulmonary vascular remodeling developed as the response to some sort of stimulus
[2,3]. This can be supported by the facts that only a few
cases of BMPR2 mutation carriers developed clinical disease [4] and BMPR2-knockdown mice did not develop
pulmonary artery medial hypertrophy, spontaneously
[29]. Since remodeling of pulmonary artery in our model
may be a sequel to inoculation of nonpathogenic fungus,
down regulation of BMPR2 signaling should be simply
understood as a consequence of muscularization which
might be induced by alteration of signaling pathways at
the upper stream. Besides BMP signaling, four more
pathways known as identical expression patterns in
IPAH were found in our PAH model. It has been suggested that inflammation might participate in the onset
and propagation of pulmonary vascular remodeling in
PAH via the JAK/STAT pathway [37,38], because elevated levels of inflammatory cytokines could trigger inflammation that is characteristic of PAH of both
connective tissue disease-associated [39] and Virusassociated [40]. While PAH is up to threefold more
prevalent in women than men [41], the increased

Shimodaira et al. Respiratory Research 2012, 13:103
http://respiratory-research.com/content/13/1/103

Page 8 of 12

Table 2 The top 10 most up-regulated and downregulated genes

Table 3 Events (reactions and/or pathways) associated
with up-regulated and down-regulated genes

Fold-Change*

Description

Event ID* Event Name†

[Up-regulated Genes]

Gene Symbol

[Up-regulated Genes]
72.4

Ear11

Eosinophil-associated,
ribonuclease A family, member 11

46.1

Mmp12

Matrix metallopeptidase 12

P value Input
Total
Genes in No. of
‡
Event
Genes§

98458

Immune System

1.5e-04

24

478

86456

Integrin alpha X
beta 2 binds JAM-C

7.2e-03

2

6

11.5

Rgs1

Regulator of G-protein signaling 1

11.4

Ccl9

Chemokine ligand 9

108524

GPCR ligand binding

3.0e-02

13

322

10.3

Ccl8

Chemokine ligand 8

104591

2

13

Igj

Immunoglobulin joining chain

Eicosanoid
ligand-binding receptors

3.8e-02

10.0
9.0

Igf1

Insulin-like growth factor 1

23802

5.1e-04

2

2

8.2

Gpnmb

Glycoprotein nmb

Mouse JAK2 binds human
common beta chain

8.2

Ccl11

Chemokine ligand 11

89750

Hemostasis

1.5e-03

19

400

8.2

Ccl22

Chemokine ligand 22

33150

Endogenous sterols

3.4e-02

2

13

108993

Vitamin B2 metabolism

2.9e-03

2

4

111211

Stat5 tyrosine
phosphorylation

4.9e-03

2

5

115537

IL7ra is phosphorylated
on Y449

4.9e-03

2

5

81332

Ubiquitination of
phospho-p27/p21

1.6e-02

2

9

107910

Synthesis, Secretion, and
Deacylation of Ghrelin

2.0e-02

2

10

3.9e-06

26

353

[Down-regulated Genes]
4.2

Bex2

Brain expressed X-linked 2

3.1

Upk3b

Uroplakin 3B

2.9

Rrm2b

Ribonucleotide reductase M2 B

2.7

Lgals2

Lectin, galactoside-binding, soluble, 2

2.7

Acaa1b

Acetyl-Coenzyme A acyltransferase 1B

2.3

Shisa2

Shisa homolog 2

2.2

Ssr1

Signal sequence receptor, alpha

[Down-regulated Genes]

2.2

Kcnip4

Kv channel interacting protein 4

92778

Axon guidance

2.2

Msln

Mesothelin

95727

Myogenesis

4.9e-02

2

13

2.1

Fam82b

Family with sequence
similarity 82 member

90528

Signaling by VEGF

4.7e-04

4

14

2.1

Upk1b

Uroplakin 1B

100071

Integrin cell surface
interactions

7.1e-03

9

123

2.1

Vldlr

Very low density lipoprotein receptor

82568

PDGF binds to extracellular
matrix proteins

3.6e-02

4

45

118126

I-Smad competes with
R-Smad1/5/8 for
type I receptor

1.9e-02

2

8

91050

SOS phosphorylation and
dissociation

7.3e-03

2

5

112933

Cell-Cell communication

1.7e-02

8

118

95483

Metabolism of nitric oxide

3.0e-02

2

10

84093

Ethanol oxidation

1.1e-03

3

8

79841

FMO oxidizes nucleophiles

2.3e-03

2

3

97703

Apoptotic execution phase

1.1e-02

5

49

107112

Aquaporin-mediated transport 8.0e-03

4

29

84730

MAPK targets/ Nuclear events
mediated by MAP kinases

3

30

*Fold change values are calculated by dividing the experimental group values
by the control values.

expression of molecules associated with the estrogen signaling pathway are reported in both genders of patients
with IPAH [15]. In addition, the evidence implicating
serotonin has been discussed with correlation to the
anorexigenic drugs aminorex and fenfluramine [42]. As
with alteration of BMP signaling, the altered expression
of these pathways would be simply associated with the
consequence of pulmonary vascular remodeling developed as the response to some sort of stimulus. It might
be better to understand as a sequel to vascular remodeling because that coagulation activity could be activated
by various stimuli such as a cytokine and endothelial
dysfunction [43].
On the other hand, it emerged that some discrepant
gene expression patterns between those previously
known in IPAH and our model. Four pathways were
identified as those altered alone in IPAH which comprised up-regulations of the Wnt/planar cell polarity
(PCP) signaling pathway [27], the Ras homolog (Rho)/

5.0e-02

*Reactome event accession number.
†
Event name according to the Reactome Database.
‡
Number of regulated genes in this model.
§
Total number of genes involved in the event.
JAM: Junctional adhesion molecule, GPCR: G protein coupled receptors, JAK:
Janus kinase, VEGF: Vascular endothelial growth factor, PDGF: platelet-derived
growth factor, SOS: Son of Sevenless proteins, FMO: Flavin Monooxygenases,
MAPK: mitogen-activated protein kinase, MAP: Mitogen-activated protein.
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Table 4 Quantitative PCR Validation of Microarray
Expression data

Table 5 Events (reactions and/or pathways) and the
expression patterns in IPAH and in our PAH model

Gene symbol Gene Name

Fold Change (P value)*

ID*

Event Name†

IPAH‡

Present model

RT-PCR

Microarray

map04630

JAK/STAT signaling

Up

UP

REACT_604

Hemostasis

Up

Up

GO:0030520

Estrogen receptor
signaling pathway

Up

Up

GO:0007210

Serotonin receptor
signaling pathway

Up

Up

Up

Not identified

Acvrl1

Activin A receptor,
type II-like 1

0.7(0.07)

0.7(0.05)

Bmpr2

Bone morphogenic
protein receptor, type II

0.6(0.04)

0.8(0.04)

Eng

Endoglin

0.5(0.05)

0.7(0.05)

Ccl8

Chemokine ligand 8

14.0(0.06)

10.3(0.04)

GO:0001666

Response to hypoxia

Ccl9

Chemokine ligand 9

9.5(0.03)

11.4(0.02)

map04310

Wnt/PCP pathway

Up

Not identified

Ear11

Eosinophil-associated,
ribonuclease A family,
member 11

76.0(0.04)

72.4(0.02)

REACT_19389

ROCK activation by Rho

Up

Not identified

REACT_16888

Signaling by PDGF

Up

Down

REACT_12529

Signaling by VEGF

Up

Down

GO:0042981

Regulation of
apoptotic process

Up/Down

Down

Igj

Immunoglobulin
joining chain

Mmp12
Mmp13
Mmp19

20.5(0.26)

10.0(0.05)

Matrix metallopeptidase 12

104.6(0.05)

46.1(0.02)

Matrix metallopeptidase 13

5.1(0.17)

5.7(0.05)

REACT_12034

Signaling by BMP

Down

Down

2.9(0.05)

REACT_6844

Signaling by TGF beta

Down

Not identified

*Accession number of Reactome, KEGG, and GO.
†
Event name according to the Reactome, KEGG, and GO Database.
‡
Expression pattern of biological molecules associated with the event in lung
tissue obtained from patients with IPAH in previously published reports
JAK/STAT: Janus kinase-signal transducer and activator of transcription, PCP:
planar cell polarity, ROCK: Ras Homolog- Associated Coiled-Coil-Forming
Protein Kinase, Rho: Ras Homolog, PDGF: Platelet-derived growth factor, VEGF:
Vascular endothelial growth factor, BMP: Bone morphogenetic protein, TGF:
Transforming growth factor.

Matrix metallopeptidase 19

3.1(0.05)

Nos3

Nitric oxide synthase 3,
endothelial cell

0.7(0.09)

0.8(0.17)

Pdgfa

Platelet derived
growth factor, alpha

0.7(0.01)

0.8(0.07)

Vegfa

Vascular endothelial
growth factor A

0.6(<0.01)

0.7(0.04)

Gapdh†

Glyceraldehyde-3-phosphate
dehydrogenase

1.0(<0.01)

0.9(0.46)

*Fold change values are calculated by dividing the experimental group values
by the control values. Statistical analyses were performed by non-paired t-tests
†
Gapdh was used as an internal control.

Rho- Associated Coiled-Coil-Forming Protein Kinase
(ROCK) pathway [26,27], and the hypoxia response
pathway [23,24], and down-regulations of the transforming growth factor beta (TGFB) signaling pathway [16].
Both PDGF signaling pathway [25] and VEGF signaling
pathway [15,26] were found as those up-regulated in
IPAH and down-regulated in this model. Interestingly,
not detected was a pathway showing the reverse pattern.
Among these various pathways, we would focus on the
Wnt/PCP pathway as the essential pathway of pathogenesis in IPAH because this pathway is presently known to
be in the upper levels of hierarchical pathways regulating
other related pathways [12-14]. Laumanns et al. reported
that microarray analysis of lung tissue from patients with
IPAH demonstrated the contribution of this pathway to
the pathogenesis of IPAH [27]. It has been reported Wnt
family of signaling proteins is essential for organ development in general, and lung morphogenesis in particular
[44]. Especially, the PCP pathway signals through activation of the Rho/ROCK signaling pathway are implicated
in cytoskeletal organization and epithelial cell polarity.
In addition, this pathway has been shown to be required
for normal lung development, and reports are beginning

to emerge of links between PCP pathways and lung disease [45]. Besides IPAH, PCP gene expression changes
were observed within isolated pulmonary vasculature in
patients with pulmonary fibrosis. Studies of patients with
IPAH have shown significant up-regulation of PCP signaling [27] and down-regulation of TGFB signaling [16].
Investigations have also shown inhibition of canonical
Wnt signaling by PCP ligands [45], crosstalk between canonical Wnt signaling and TGFB signaling [46], and recruitment of both canonical and non-canonical Wnt
pathways are required in BMP2 mediated angiogenesis
in human pulmonary artery endothelial cells [47]. A part
of results from the present study, no change of pathways
around this system can support that altered interaction
between the canonical Wnt pathway and the TGFB signaling pathway play an essential role for human disease
and further clarification is expected of the role of the
PCP pathway in the pathogenesis of IPAH. On the other
hand, some previous reports conducted human disease
reported the Rho/ROCK signaling pathway is also activated, but it is known that many other stimuli can activate this system [48]. An activation of this pathway may
conduct to smooth muscle cell proliferation in pulmonary artery [49], we wish to understand this event as secondary episode to alteration in PCP signaling pathways.
Although, the details in the mechanism is unclear,
various factors (e.g., Hypoxia, inflammation, and shear
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Table 6 Summarized events (reactions and/or pathways) and the expression patterns in previously rat models
ID*

Event Name†

Hypoxia-induced model‡

Hypoxia-induced model§

MCT-induced model¶

map04630

JAK/STAT signaling

Not identified

Not identified

Not identified

REACT_604

Hemostasis

Down

Up/Down

Up/Down

GO:0030520

Estrogen receptor signaling pathway

Up

Not identified

Down

GO:0007210

Serotonin receptor signaling pathway

Up/Down

Not identified

Down

GO:0001666

Response to hypoxia

Up/Down

Up

Down

map04310

Wnt/PCP pathway

Not identified

Not identified

Not identified

REACT_19389

ROCK activation by Rho

Up

Not identified

Down

REACT_16888

Signaling by PDGF

Up

Up/Down

Down

REACT_12529

Signaling by VEGF

Not identified

Not identified

Down

GO:0042981

Regulation of apoptotic process

Up/Down

Not identified

Up/Down

REACT_12034

Signaling by BMP

Up/Down

Not identified

Not identified

REACT_6844

Signaling by TGF beta

Up

Up

Up

*Accession number of Reactome, KEGG, and GO.
†
Event name according to the Reactome, KEGG, and GO Database.
‡
Hypoxia-induced rat models reported by Moreno-Vinasco et al [31].
§
Hypoxia-induced rat models reported by Kwapiszewska et al [32].
¶
MCT-induced rat models reported by Vaszar et al [33].
JAK/STAT: Janus kinase-signal transducer and activator of transcription, PCP: planar cell polarity, ROCK: Ras Homolog- Associated Coiled-Coil-Forming Protein
Kinase, Rho: Ras Homolog, PDGF: Platelet-derived growth factor, VEGF: Vascular endothelial growth factor, BMP: Bone morphogenetic protein, TGF: Transforming
growth factor, MCT: Monocrotaline.

stress) are known as the inducer of growth factors such
as VEGF and PDGF [50,51]. Accordingly, their activation
may not be essential because they usually play at the
lower level of hierarchical pathways, which are activated
by many sorts of stimuli.

Conclusion
Discrepancy in gene expression pattern between this
model and the human disease previously reported suggests that activation of Rho/ROCK signaling via Wnt/PCP
signaling plays an essential role in pathogenesis of IPAH.
Additional file
Additional file 1: Expression pattern of biological molecules in lung
tissue obtained from patients with IPAHand related pathways.
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